Valneva SE (NASDAQ:VALN) to Post Q3 2024 Earnings of ($0.29) Per Share, HC Wainwright Forecasts

Valneva SE (NASDAQ:VALN) – Analysts at HC Wainwright raised their Q3 2024 EPS estimates for shares of Valneva in a research note issued to investors on Wednesday, September 25th. HC Wainwright analyst E. White now expects that the company will earn ($0.29) per share for the quarter, up from their previous forecast of ($0.31). HC Wainwright has a “Buy” rating and a $23.00 price target on the stock. The consensus estimate for Valneva’s current full-year earnings is $0.02 per share. HC Wainwright also issued estimates for Valneva’s Q4 2024 earnings at ($0.20) EPS, FY2025 earnings at ($1.14) EPS and FY2026 earnings at ($0.38) EPS.

Valneva (NASDAQ:VALN) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.02. Valneva had a negative return on equity of 20.01% and a negative net margin of 21.31%. The company had revenue of $40.97 million during the quarter, compared to the consensus estimate of $46.83 million.

Valneva Stock Up 1.6 %

Shares of VALN opened at $6.21 on Friday. Valneva has a 12 month low of $5.70 and a 12 month high of $14.49. The company has a current ratio of 2.63, a quick ratio of 2.15 and a debt-to-equity ratio of 0.97. The company has a market capitalization of $432.46 million, a PE ratio of -15.15 and a beta of 2.19. The stock’s 50-day moving average price is $7.06 and its two-hundred day moving average price is $7.57.

Institutional Investors Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC raised its position in shares of Valneva SE (NASDAQ:VALN) by 42.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 88,252 shares of the company’s stock after acquiring an additional 26,248 shares during the quarter. AlphaCentric Advisors LLC owned about 0.13% of Valneva worth $649,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.